Table 3. Summary of PROTACs in Clinical Trials64,65.
| PROTACs | Target protein | E3 ligase | Phase | Company | Indication |
|---|---|---|---|---|---|
| ARV-471 | ER | CRBN | III | Arvinas | Breast cancer |
| ARV-110 | AR | CRBN | II | Arvinas | Prostate cancer |
| ARV-766 | AR | CRBN | I | Arvinas | Prostate cancer |
| CC-94676 | AR | CRBN | I | Bristol Myers, Sqibb | Prostate cancer |
| DT2216 | BCL-XL | VHL | I | Dialectic | T cell lymphomas |
| FHD-609 | BRD9 | - | I | Foghorn | Synovial sarcoma |
| CFT-8634 | BRD9 | CRBN | I | C4 Therapeutics | Synovial sarcoma |
| NX-2127 | BTK, IKZF1/3 | CRBN | I | Nurix | B- cell malignancies |
| BGB-16673 | BTK | NA | I | BeiGene | B-cell malignancies |
| NX-5948 | BTK | CRBN | I | Nurix | B-cell malignancies and autoimmune diseases |
| HSK29116 | BTK | NA | I | Haisco | B-cell malignancies |
| KT-474 | IRAK4 | CRBN | I | Kymera | Immuno-inflammatory skin disease |
| KT-413 | IRAK4, IKZF1/3 | CRBN | I | Kymera | MYD88 mutant tumors |
| KT-333 | STAT3 | NA | I | Kymera | Liquid and solid tumors, T cell lymphomas |
| CG001419 | TRK | CRBN | I | Cullgen | - |
| AC-0176 | AR | CRBN | I | Accutar | Prostate cancer |
| HP518 | AR | CRBN | I | Hinova | Prostate cancer |
| GT20029 | AR | CRBN | I | Kintor | Androgenetic alopecia and acne vulgaris |
| CFT-1946 | BRAF V600 | CRBN | I | C4 Therapeutics | BRAF V600 mutant solid tumors, nonsmall-cell lung cancer, colorectal cancer and melanoma |